Evaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid Arthritis

Stopped AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to Rigel Pharmaceuticals.

Conditions

• Rheumatoid Arthritis

Interventions

• DRUG: Fostamatinib
• DRUG: Fostamatinib
• DRUG: Fostamatinib
• DRUG: Fostamatinib
• DRUG: Placebo

Sponsor

AstraZeneca